Moreover, SP600125, a c-Jun N-terminal kinase (JNK) inhibitor [31], was found to influence c-Jun activity in SCs and to impede PNI in vivo, demonstrating the potential for targeted therapies in pancreatic cancer. This evidence concerns the gene JUN and familial pancreatic carcinoma.